Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics announced that its CHM CDH17 therapy has received Fast Track Designation from the U.S. FDA for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This designation is expected to expedite the development and review process, potentially leading to accelerated approval and priority review, thereby enhancing the company’s ability to bring this promising therapy to patients sooner.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical-stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company has a diverse portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across multiple oncology areas.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.06M
See more insights into CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue